Respirology (Carlton, Vic.) · 2026
Predicting Failure at Initiation of High-Flow Nasal Oxygen in Patients With COVID-19: Literature Review, Development and Internal Validation of a Prediction Model.
СтатьяНаблюдательное исследованиеМногоцентровое исследованиеОбзорВалидационное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sjauw Daphne J T, Janssen Matthijs L, Türk Yasemin, Reep Carmen A T, Heunks Leo, Baart Sara J, Wils Evert-Jan, Dutch HFNO study group, NORMO2 project group
Аннотация
BACKGROUND AND OBJECTIVE: High-Flow Nasal Oxygen (HFNO) can reduce the need for invasive mechanical ventilation in patients with acute hypoxemic respiratory failure (AHRF) from viral pneumonias, like COVID-19. Early prediction of HFNO failure is useful for timely decision-making at HFNO initiation. This study aimed to develop a prediction model for HFNO failure using predictors available just prior to HFNO initiation in patients with COVID-19 AHRF and compare its performance to existing models.
METHODS: This multicenter, prospective observational cohort study included hospitalized patients from 10 centers in the Netherlands between December 2020 and July 2021. Adults who tested positive for SARS-CoV-2, had no treatment limitations, and initiated HFNO for hypoxemia were included. The primary outcome was HFNO failure, defined as the event of endotracheal intubation. Pre-defined candidate predictors were selected by multivariable logistic regression for prediction model development. Internal validation was conducted using bootstrapping.
RESULTS: Out of 608 patients, 277 (46%) experienced HFNO failure. Independent predictors of HFNO failure included (odds ratio [95% CI]): age (1.02 [1.00-1.03]), urea (1.04 [1.00-1.08]), platelet count (0.94 [0.92-0.97]), respiratory rate (1.05 [1.02-1.08]), oxygen saturation (0.89 [0.84-0.94]), and FiO2 (conventional oxygen 10-15 L/min vs. < 10 L/min: 3.00 [1.71-5.29], 15 L/min vs. < 10 L/min: 4.95 [3.19-7.70]) prior to HFNO initiation. The model C-statistic was 0.767; 95% CI [0.727-0.803], with excellent calibration (intercept: -0.005, slope: 1.001), and stable performance after internal validation.
CONCLUSIONS: This newly developed model, using variables available at HFNO initiation, effectively predicted HFNO failure in hospitalized hypoxemic patients due to COVID-19 pneumonia with good performance.
REGISTRATION NUMBER CLINICAL TRIAL: Dutch Trial Registry: DTR, NL9067.
METHODS: This multicenter, prospective observational cohort study included hospitalized patients from 10 centers in the Netherlands between December 2020 and July 2021. Adults who tested positive for SARS-CoV-2, had no treatment limitations, and initiated HFNO for hypoxemia were included. The primary outcome was HFNO failure, defined as the event of endotracheal intubation. Pre-defined candidate predictors were selected by multivariable logistic regression for prediction model development. Internal validation was conducted using bootstrapping.
RESULTS: Out of 608 patients, 277 (46%) experienced HFNO failure. Independent predictors of HFNO failure included (odds ratio [95% CI]): age (1.02 [1.00-1.03]), urea (1.04 [1.00-1.08]), platelet count (0.94 [0.92-0.97]), respiratory rate (1.05 [1.02-1.08]), oxygen saturation (0.89 [0.84-0.94]), and FiO2 (conventional oxygen 10-15 L/min vs. < 10 L/min: 3.00 [1.71-5.29], 15 L/min vs. < 10 L/min: 4.95 [3.19-7.70]) prior to HFNO initiation. The model C-statistic was 0.767; 95% CI [0.727-0.803], with excellent calibration (intercept: -0.005, slope: 1.001), and stable performance after internal validation.
CONCLUSIONS: This newly developed model, using variables available at HFNO initiation, effectively predicted HFNO failure in hospitalized hypoxemic patients due to COVID-19 pneumonia with good performance.
REGISTRATION NUMBER CLINICAL TRIAL: Dutch Trial Registry: DTR, NL9067.